美康生物(300439) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥374,030,860.65, a decrease of 22.32% compared to ¥481,512,053.72 in the same period last year[5] - Net profit attributable to shareholders was ¥30,397,722.74, down 61.57% from ¥79,096,771.20 year-on-year[5] - The total comprehensive income for the period was ¥28,621,792.87, down from ¥78,072,635.19, reflecting a decline of approximately 63.3% year-over-year[22] - Net profit for the period was ¥29,779,054.03, down from ¥78,052,111.07, reflecting a decline of approximately 61.9% year-over-year[22] - Basic and diluted earnings per share both decreased to ¥0.08 from ¥0.21, a drop of approximately 61.9%[23] - Total operating revenue decreased to ¥374,030,860.65 from ¥481,512,053.72, representing a decline of approximately 22.3% year-over-year[21] - Total operating costs reduced to ¥350,212,593.71 from ¥412,341,013.66, a decrease of about 15.1% year-over-year[21] Cash Flow - The net cash flow from operating activities was -¥46,259,188.59, a decline of 605.58% compared to ¥9,149,804.16 in the previous year[5] - Operating cash flow turned negative at -¥46,259,188.59 compared to a positive cash flow of ¥9,149,804.16 in the previous period[24] - Cash inflow from investment activities increased significantly to ¥173,477,532.06 from ¥19,168,033.97, indicating a strong recovery in investment receipts[24] - Net cash flow from investment activities was -$92,666,023.25, improving from -$138,270,881.54 year-over-year[25] - Cash inflow from financing activities was $480,000.00, compared to $30,000,000.00 in the previous period[25] - Net cash flow from financing activities was -$29,809,214.13, worsening from -$20,432,329.74 year-over-year[25] - The net increase in cash and cash equivalents was -$168,774,287.99, compared to -$149,545,907.62 in the previous period[25] - The ending balance of cash and cash equivalents was $557,840,748.36, down from $802,778,150.63 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,587,941,696.34, a decrease of 3.16% from ¥3,705,114,506.80 at the end of the previous year[5] - Current assets decreased from CNY 1,824,194,344.46 to CNY 1,721,424,797.37, representing a decrease of about 5.63%[18] - Cash and cash equivalents decreased from CNY 728,636,326.23 to CNY 559,862,038.24, a reduction of approximately 23.2%[18] - Total liabilities decreased from CNY 771,646,162.98 to CNY 624,691,078.45, a decline of about 19.05%[19] - The company's equity attributable to shareholders increased from CNY 2,939,828,873.18 to CNY 2,970,496,731.95, an increase of approximately 1.04%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,048, with the largest shareholder holding 28.36% of the shares[14] Operational Strategy - The company plans to enhance refined management and optimize the supply chain to improve operational efficiency and increase market share in the biochemical and immunological product sectors[9] - The company aims to accelerate its overseas market expansion as part of its growth strategy[9] Other Financial Metrics - The weighted average return on equity was 1.03%, down from 2.87% in the same period last year, reflecting a decrease of 1.84%[5] - The company reported a significant increase in government subsidies, amounting to ¥11,172,090.16, a rise of 67.84% compared to ¥6,656,517.70 in the previous year[12] - The company experienced a 487.93% increase in notes receivable, reaching ¥1,393,694.65, primarily due to settlements using commercial acceptance bills[11] - Accounts receivable increased from CNY 553,022,297.52 to CNY 566,641,388.55, an increase of about 2.02%[18] - Inventory decreased from CNY 286,010,777.60 to CNY 271,270,681.93, a decrease of approximately 5.15%[18] - The deferred income tax assets increased from CNY 40,748,986.09 to CNY 49,302,563.68, an increase of about 21.3%[19] - The company's retained earnings increased from CNY 1,323,727,670.30 to CNY 1,354,125,393.04, an increase of approximately 2.29%[20] - Research and development expenses were ¥35,830,195.42, down from ¥38,296,282.28, a reduction of about 12.8% year-over-year[21] - Other income increased to ¥11,172,090.16 from ¥6,656,517.70, marking an increase of approximately 67.5% year-over-year[21] - The company reported an investment loss of ¥2,738,528.61 compared to a gain of ¥1,680,076.74 in the previous period, indicating a significant downturn in investment performance[21] Accounting and Reporting - The first quarter report was not audited[26] - The company will implement new accounting standards starting in 2025[27]